MAPK8 and head and neck squamous cell carcinoma: A recent study showed JNK activation as the possible etiology of Cetuximab therapy resistance in head and neck squamous cell carcinomas (HNSCCs), which exhibit loss of Smad4 and aggressive phenotype29.